Skip to main content

FDA advisers vote in favor of Pfizer’s maternal RSV vaccine

If approved, vaccine would be the first in U.S. to protect babies against leading cause of hospitalization
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.